Stock Financial Ratios, Dividends, Split History

XXII / 22nd Century Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)343.10
Book Value ($M)75.43
Book Value / Share0.61
Price / Book4.42
NCAV ($M)63.31
NCAV / Share0.51
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 124,136,087
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Weighted Average Number Of Shares Outstanding Basic 101,161,380
Common Stock Shares Outstanding 123,569,367
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.17
Return on Assets (ROA)-0.47
Return on Equity (ROE)-0.54
Balance Sheet (mrq) ($M)
Quick Ratio14.92
Current Ratio15.68
Income Statement (mra) ($M)
Sales Revenue Goods Net16,600,244.00
Operating Income-13.30
Net Income-13.03
Earnings Per Share Diluted-0.13
Earnings Per Share Basic-0.13
Earnings Per Share Basic And Diluted-0.13
Cash Flow Statement (mra) ($M)
Cash From Operations-12.07
Cash from Investing-60.59
Cash from Financing-60.59
Identifiers and Descriptors
Central Index Key (CIK)1347858
Related CUSIPS
90137F953 90137F903
Industry Groups
SIC 2111 - Cigarettes

Split History

Stock splits are used by 22nd Century Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
XXII : 22nd Century Group Stock Analysis and Research Report

2017-10-09 - Asif

22nd Century Group is a plant biotechnology company focused on (i) potentially reduced risk tobacco cigarettes and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding, and (ii) research and development of unique cannabis/hemp plants through genetic engineering and plant breeding to alter levels of cannabinoids for new medicines and improved agricultural uses. The company has an extensive intellectual property portfolio of issued patents and patent applications relating to the tobacco and cannabis plants. Its management team is focused on monetizing its intellectual property portfolio, obtaining regulatory approval to market both its reduced exposure cigarettes and its smoking cessation product in development, and developing and commercializing high value products derived from its unique cannabis/hemp plants. Additional information about its business and operations is contained in tis Annual Report on ...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Is Vector Group Dividend For Real?

2018-06-18 seekingalpha
The company’s business model consists of investing the proceeds from their discount cigarette business into a high-end real estate business. (389-1)

SHU Portfolio: An Update On 22nd Century Group

2018-05-07 seekingalpha
It's an attractive risk/reward play but the underlying story warrants patience but we still think that will pay off. (381-8)

22nd Century Group's (XXII) CEO Henry Sicignano on Q1 2018 Results - Earnings Call Transcript

2018-05-05 seekingalpha
22nd Century Group, Inc. (NYSEMKT:XXII) Q1 2018 Results Conference Call May 3, 2018 4:00 PM ET (383-4)

CUSIP: 90137F103